Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers

Journal of Infection and Chemotherapy

Volumn 21, Issue 8, 2015, Pages 551-558

  Tominaga, Nobumitsu ^a   Edeki, Timi ^a   Li, James ^a   Learoyd, Maria ^a   Bouw, M René ^b   Das, Shampa ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Avibactam; Ceftazidime; Japanese; Pharmacokinetics; Safety; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AVIBACTAM; CEFTAZIDIME; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ACCUMULATION RATIO; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; AREA UNDER THE CURVE RATIO; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTACT DERMATITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELIMINATION HALF-LIFE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; INJECTION SITE EXTRAVASATION; INJECTION SITE THROMBOSIS; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; URINARY EXCRETION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; JAPAN; MIDDLE AGED; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; DOUBLE-BLIND METHOD; GAMMA-GLUTAMYLTRANSFERASE; HEALTHY VOLUNTEERS; HUMANS; HYPOTENSION, ORTHOSTATIC; JAPAN; MALE; MIDDLE AGED; TACHYCARDIA; YOUNG ADULT;

EID: 84937627900     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.04.006     Document Type: Article

References (35)

1. Hsueh P.R., Hoban D.J., Carmeli Y., Chen S.Y., Desikan S., Alejandria M., et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. JInfect 2011, 63:114-123.
2. Liu Y.M., Chen Y.S., Toh H.S., Huang C.C., Lee Y.L., Ho C.M., et al. Invitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012, 40(Suppl):S11-S17.
3. Lu P.L., Liu Y.C., Toh H.S., Lee Y.L., Liu Y.M., Ho C.M., et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012, 40(Suppl):S37-S43.
4. Rosenthal V.D., Bijie H., Maki D.G., Mehta Y., Apisarnthanarak A., Medeiros E.A., et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012, 40:396-407.
5. Sheng W.H., Badal R.E., Hsueh P.R. Distribution of extended-spectrum b-lactamases, AmpC b-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013, 57:2981-2988.
6. Fujiwara M., Mizunaga S., Nomura N., Mitsuyama J., Hashido H., Yamaoka K., et al. Sensitivity surveillance of Pseudomonas aeruginosa isolates for several antibacterial agents in Gifu and Aichi prefecture (2008). Jpn J Antibiot 2012, 65:15-26.
7. Kuroda H., Yano H., Hirakata Y., Arai K., Endo S., Kanamori H., et al. Molecular characteristics of extended-spectrum b-lactamase-producing Escherichia coli in Japan: emergence of CTX-M-15-producing E.coli ST131. Diagn Microbiol Infect Dis 2012, 74:201-203.
8. Izumida M., Nagai M., Ohta A., Hashimoto S., Kawado M., Murakami Y., et al. Epidemics of drug-resistant bacterial infections observed in infectious disease surveillance in Japan, 2001-2005. JEpidemiol 2007, 17(Suppl):S42-S47.
9. Nakano R., Nakano A., Abe M., Inoue M., Okamoto R. Regional outbreak of CTX-M-2 b-lactamase-producing Proteus mirabilis in Japan. JMed Microbiol 2012, 61:1727-1735.
10. Watanabe A., Yanagihara K., Matsumoto T., Kohno S., Aoki N., Oguri T., et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens' antibacterial susceptibility. JInfect Chemother 2012, 18:609-620.
11. Bush K. Proliferation and significance of clinically relevant b-lactamases. Ann N Y Acad Sci 2013, 1277:84-90.
12. Kanj S.S., Kanafani Z.A. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum b-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011, 86:250-259.
13. Gutkind G.O., Di C.J., Power P., Radice M. b-Lactamase-mediated resistance: a biochemical, epidemiological and genetic overview. Curr Pharm Des 2013, 19:164-208.
14. Matsumura Y., Yamamoto M., Higuchi T., Komori T., Tsuboi F., Hayashi A., et al. Prevalence of plasmid-mediated AmpC b-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum b-lactamase-producing E.coli in Japan. Int J Antimicrob Agents 2012, 40:158-162.
15. Vardakas K.Z., Tansarli G.S., Rafailidis P.I., Falagas M.E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum b-lactamases: a systematic review and meta-analysis. JAntimicrob Chemother 2012, 67:2793-2803.
16. Nordmann P., Naas T., Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798.
17. Ehmann D.E., Jahic H., Ross P.L., Gu R.F., Hu J., Kern G., et al. Avibactam is a covalent, reversible, non-b-lactam b-lactamase inhibitor. Proc Natl Acad Sci U S A 2012, 109:11663-11668.
18. Lahiri S.D., Mangani S., Durand-Reville T., Benvenuti M., De L.F., Sanyal G., et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC b-lactamases. Antimicrob Agents Chemother 2013, 57:2496-2505.
19. Zhanel G.G., Lawson C.D., Adam H., Schweizer F., Zelenitsky S., Lagace-Wiens P.R., et al. Ceftazidime-avibactam: a novel cephalosporin/b-lactamase inhibitor combination. Drugs 2013, 73:159-177.
20. Endimiani A., Hujer K.M., Hujer A.M., Pulse M.E., Weiss W.J., Bonomo R.A. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:82-85.
21. Lagace-Wiens P.R., Tailor F., Simner P., DeCorby M., Karlowsky J.A., Walkty A., et al. Activity of NXL104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum b-lactamases and class C b-lactamases. Antimicrob Agents Chemother 2011, 55:2434-2437.
22. Livermore D.M., Mushtaq S., Warner M., Zhang J., Maharjan S., Doumith M., et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011, 55:390-394.
23. Stachyra T., Levasseur P., Pechereau M.C., Girard A.M., Claudon M., Miossec C., et al. Invitro activity of the b-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. JAntimicrob Chemother 2009, 64:326-329.
24. Lucasti C., Popescu I., Ramesh M.K., Lipka J., Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. JAntimicrob Chemother 2013, 68:1183-1192.
25. Vazquez J.A., Gonzalez Patzan L.D., Stricklin D., Duttaroy D.D., Kreidly Z., Lipka J., et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012, 28:1921-1931.
26. Das S., Armstrong J., Mathews D., Li J., Edeki T. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. JClin Pharmacol 2014, 54:331-340.
27. Edeki T., Armstrong J., Li J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers 2013, 53rd international conference on antimicrobial agents and chemotherapy (ICAAC), September 10-13, 2013, Denver, CO, USA. [Abstract A-1019].
28. Li J., Armstrong J., Edeki T. Pharmacokinetic (PK) drug interaction study of ceftazidime-avibactam (CAZ-AVI) and metronidazole (MTZ) in healthy volunteers 2013, Poster presented at the 53rd international conference on antimicrobial agents and chemotherapy (ICAAC), September 10-13, 2013, Denver, CO, USA.
29. Merdjan H., Rangaraju M., Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Invest 2015, 35:307-317.
30. Nicolau D.P., Siew L., Armstrong J., Edeki T., Bouw R. Concentration of avibactam (AVI) and ceftazidime (CAZ) in plasma and epithelial lining fluid (ELF) in healthy volunteers 2013, International conference on antimicrobial agents and chemotherapy (ICAAC), September 10-13, 2013, Denver, CO, USA. [Abstract A-1027].
31. Tarral A., Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther 2015, 37:877-886.
32. Endimiani A., Choudhary Y., Bonomo R.A. Invitro activity of NXL104 in combination with b-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009, 53:3599-3601.
33. Levasseur P., Girard A.M., Miossec C., Pace J., Coleman K. Invitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized beta-lactamases. Antimicrob Agents Chemother 2015, 59:1931-1934.
34. Coleman K., Levasseur P., Girard A.M., Borgonovi M., Miossec C., Merdjan H., et al. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 2014, 58:3366-3372.
35. AVYCAZ Prescribing Information Available at:, [accessed 16.03.15]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494lbl.pdf.